SCHEMBL23258769

SCHEMBL23258769

Cc1cccc(F)c(=O)c1OC(=O)OC(C)(C)C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ELANE P08246 1/20 0.40
▸ KDM4E B2RXH2 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ L3MBTL1 Q9Y468 2/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ KMT2A Q03164 2/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ SCN8A Q9UQD0 2/20 0.33
▸ SCN10A Q9Y5Y9 2/20 0.33
▸ HTR1A P08908 2/20 0.33
▸ SLC6A2 P23975 2/20 0.33
▸ SLC6A4 P31645 2/20 0.33
▸ KAT6A Q92794 1/20 0.33
▸ ACHE P22303 1/20 0.32
▸ SCN5A Q14524 1/20 0.32
▸ SCN9A Q15858 1/20 0.32
▸ PTPN1 P18031 1/20 0.32
▸ GCK P35557 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2761277 0.84 ELANE (0.49) ELANEKDM4EALDH1A1HPGDHSD17B10
SCHEMBL23258470 0.84 ELANE (0.39) ELANEALDH1A1HPGDHSD17B10KMT2A
SCHEMBL23259156 0.82 ELANE (0.40) ELANEKDM4EALDH1A1HPGDHSD17B10
SCHEMBL23258467 0.82 SCN5A (0.40) ELANESCN10ASCN5ASCN9A
SCHEMBL23258465 0.81 ELANE (0.36) ELANEKDM4EALDH1A1HPGDHSD17B10
SCHEMBL23263198 0.80 HSPB1 (0.41) SCN8ASCN10ASCN9A
SCHEMBL27281232 0.77 ELANE (0.42) ELANEKDM4EALDH1A1HPGDHSD17B10
SCHEMBL23263854 0.77 GAA (0.39) ELANEKDM4EALDH1A1HPGDHSD17B10
SCHEMBL23628555 0.76 KDM4E (0.64) ELANEKDM4EALDH1A1HPGDHSD17B10
SCHEMBL15867195 0.76 KDM4E (0.47) ELANEKDM4EALDH1A1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018105-A1 TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS KINESID THERAPEUTICS, INC. (US) 2024-01-18 — — US disclosed
US-20240018105-A1 TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS KINESID THERAPEUTICS, INC. (US) 2024-01-18 — — US disclosed
WO-2021076938-A1 TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS Ambys Medicines, Inc. (US) 2021-04-22 — — WO disclosed
WO-2021076945-A1 TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS Ambys Medicines, Inc. (US) 2021-04-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018105-A1 TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS TXNRD2, TXNRD1, SDHB ELANE 4033/4885KDM4E 2814/4885ALDH1A1 848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback